Save the Date!
Cholangiocarcinoma Foundation Annual Conference
February 4-5, 2016
Salt Lake City, Utah
2015 Annual Conference in Review
Welcome to the Conference/Foundation Updates
Dr. Robin Kim, Huntsman Cancer Institute
Dr. Milind Javle, MD Anderson Cancer Center – Conference Chair
Stacie Lindsey, President, The Cholangiocarcinoma Foundation
Somatic Mutation Profiling in Cholangiocarcinoma
Dr. Laura Wood, Johns Hopkins University School of Medicine
Oral Abstract Presentation - Massive Parallel Sequencing Uncovers Actionable FGFR2-PPHLN1 Fusion and ARAF Mutations in Intrahepatic Cholangiocarcinoma
Tumor Profiling and Investigational Therapeutics
Dr. Funda Meric-Bernstam, MD Anderson Cancer Center
BAP1 Mutations-Spectrum and Biology in Cancer
Dr. Michele Carbone, University of Hawaii
No presentation is available at this time.
Clinical Trials in Cholangiocarcinoma: ABC Experience
Dr. John Bridgewater, UCL Cancer Institute
No slides available at this time
Oral Abstract Presentation - Gemcitabine, Capecitabine & Bevacizumab in Patients with Advanced BC- Final Results of a Multicenter Phase II Study
CCF Nursing Advisory Board Update
CCF Working Group Updates
Dr. Milind Javle, MD Anderson – Conference Chair
Dr. Lipika Goyal,Massachusetts General Hospital Cancer Center
Dr. Renuka Iyer, Roswell Park Cancer Institute
Dr. R. Kate (Katie) Kelley, University of California San Francisco
Dr. Kelley’s Presentation Dr. Goyal’s Presentation Dr. Iyer’s Presentation
Targeting FGFR Alterations in Cancer with a Selective FGFR Inhibitor
Dr. Randi Isaacs, Novartis Institute for BioMedical Research
IDH1 Mutation in Cholangiocarcinoma
Oral Abstract Presentation - Using Model Systems to Understand IDH Mutant Cholangiocarcinoma
Dr. Supriya Saha, Massachusetts General Hospital Cancer Center
Liver Development and Plasticity
Dr. Ben Stanger, University of Pennsylvania
Potential of Immunotherapy for Solid Tumors including Cancers of the Bile Duct
Dr. Lei Zheng, Johns Hopkins University School of Medicine
CCF Advocacy Overview
PSC and Surveillance for Cholangiocarcinoma
Oral Abstract Presentation - Conjugated Bile Acids Promote Cholangiocarcinoma Cell Invasive Growth via Activation of Sphingosine 1-phosphate Receptor 2
Oral Abstract Presentation - Retrospective Review of Treatment Given to Unresectable Cholangiocarcinoma Patients: What is the Role of Chemoradiation?
Dr. Jane Rogers, MD Anderson Cancer Center (Dr. Rachna Shroff presented on behalf of Dr. Rogers)
Increasing Clinical Trials in CCA
Dr. Andrew Zhu, Massachusetts General Hospital, Session Chair
Dr. Mitesh Borad, Mayo Clinic
Dr. Eric Collisson, University of California San Francisco
Adoptive Cell Therapy – Patient Perspective
Overview of CCF Website
Wrap-up and Next Steps
Alan Venook, UCSF
Nabeel Bardeesy, MGH
Stacie Lindsey, President, Cholangiocarcinoma Foundation